Therefore, the estimation of the contribution of CHEK2 and PALB2 pathogenic variants in hereditary breast and ovarian cancer risk is not possible based on the data presented herein, and is beyond the scope of this study. This evidence concerns the gene PALB2 and ovarian cancer.